Karyopharm Therapeutics(US:KPTI) Prnewswire·2026-01-12 12:00Core Insights - Karyopharm Therapeutics anticipates a transformative year in 2026, with significant data readouts from two Phase 3 trials expected, which could redefine treatment standards in myelofibrosis and endometrial cancer [2][10] Financial Performance - Preliminary unaudited total revenue for 2025 is estimated at approximately $145 million, with U.S. XPOVIO net product revenue expected to be around $115 million [1][14] - The company completed strategic financing transactions that extended its cash runway beyond the expected top-line readout of the Phase 3 SENTRY trial [14] Clinical Trials and Developments - The Phase 3 SENTRY trial for myelofibrosis has completed enrollment with 353 patients, evaluating selinexor in combination with ruxolitinib [6][17] - Top-line data from the SENTRY trial is expected in March 2026, which could significantly impact patient outcomes [2][10] - The Phase 3 XPORT-EC-042 trial for endometrial cancer is on track to report top-line data in mid-2026, focusing on a biomarker-driven patient population [2][20] Market Position and Strategy - Demand for XPOVIO remained consistent in 2025 compared to 2024, with approximately 60% of overall net product revenue driven by the community setting [6] - Global patient access for selinexor expanded in 2025, with favorable reimbursement decisions in Spain and China, and approvals in over 50 countries [6][24] Product Information - XPOVIO (selinexor) is a first-in-class oral exportin 1 inhibitor approved for multiple oncology indications, including multiple myeloma and diffuse large B-cell lymphoma [24][29] - The company is actively preparing for regulatory filings and commercialization efforts related to its ongoing clinical trials [2][10]